SCHEMBL25913319

SCHEMBL25913319

CCCCC(=O)Nc1ncnn2c([C@]3(C)O[C@H](CO)[C@@H](O)[C@H]3O)ccc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS2 O15393 1/20 0.47
▸ HTT P42858 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ NCOA3 Q9Y6Q9 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ L3MBTL1 Q9Y468 3/20 0.32
▸ SLC29A1 Q99808 1/20 0.32
▸ MAPK1 P28482 2/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CASP1 P29466 1/20 0.31
▸ CASP7 P55210 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24916848 0.94 TMPRSS2 (0.49) TMPRSS2HTTNCOA1NCOA3RAB9A
SCHEMBL24791013 0.89 TMPRSS2 (0.38) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL24916887 0.88 TMPRSS2 (0.38) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL25925533 0.87 TMPRSS2 (0.37) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL24917004 0.86 TMPRSS2 (0.65) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL25912044 0.86 TMPRSS2 (0.45) TMPRSS2HTTSMN1; SMN2RAB9ANPC1
SCHEMBL24916862 0.85 TMPRSS2 (0.45) TMPRSS2RAB9A
SCHEMBL25913455 0.85 TMPRSS2 (0.36) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL26200184 0.85 TMPRSS2 (0.37) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2
SCHEMBL25913910 0.85 TMPRSS2 (0.37) TMPRSS2HTTNCOA1NCOA3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-11638715-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2023-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11638715-B2 Orally-bioavailable nucleoside analogs SLC29A2, SLC29A1, PNP TMPRSS2 100/4885HTT 2401/4885NCOA1 2397/4885
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP TMPRSS2 100/4885HTT 2401/4885NCOA1 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback